更新于：2024-11-04
Diphenhydramine Hydrochloride
盐酸苯海拉明
更新于：2024-11-04
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H22ClNO |
InChIKeyPCHPORCSPXIHLZ-UHFFFAOYSA-N |
CAS号147-24-0 |
关联
144
项与 盐酸苯海拉明 相关的临床试验A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Evaluation effects of intraoperative injection of diphenhydramine and dexmedetomidine infusion at the end of the operation - on the control of agitation in patients after general anesthesia in orthognathic surgery.
Role of Diphenhydramine in Prevention of Catheter Related Bladder Discomfort
100 项与 盐酸苯海拉明 相关的临床结果
登录后查看更多信息
100 项与 盐酸苯海拉明 相关的转化医学
登录后查看更多信息
100 项与 盐酸苯海拉明 相关的专利（医药）
登录后查看更多信息
1,022
项与 盐酸苯海拉明 相关的文献（医药）2024-11-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Interaction of drug molecules with surfactants below (Benesi-Hildebrand equation) and above the critical micelle concentration (Kawamura equation)
Review
作者: Puača, Gorana ; Agatić, Zita Farkaš ; Tepavčević, Vesna ; Poša, Mihalj
Drug molecules can interact with surfactant molecules either in their monomeric form, where the Benesi-Hildebrand equation determines the binding constant, or when a micellar pseudophase is formed, where the Kawamura equation assesses the partition coefficient. Benesi-Hildebrand plots represent the differential absorbance as a function of surfactant concentration below the critical micelle concentration (CMC), while Kawamura plots show this relationship above the CMC, where the drug can influence the CMC and needs consideration. This review aims to provide an overview of methods for evaluating drug-surfactant interactions in aqueous solutions, particularly below and above the CMC, using spectroscopic data. Understanding these interactions is crucial for pharmacodynamics, affecting drug binding, enzymatic activity, and formulation. Various surfactants were analyzed with diphenhydramine hydrochloride, levofloxacin, phenothiazine, moxifloxacin, and chlorpromazine hydrochloride to determine monomeric binding constants, while sulfathiazole, sodium valproate, cefotaxime, losartan, and metformin hydrochloride were assessed for partitioning coefficient values. Errors in Benesi-Hildebrand plots may arise from considering surfactant concentrations above the CMC, while mistakes in Kawamura plots may stem from neglecting to determine the CMC in the presence of drug molecules, which can alter the surfactant's behavior.
2024-09-01Veterinary Medicine and Science
Comparative study of the effects of antitussive drugs in a canine acute cough model
Article
作者: Eki, Kent ; Aoki, Takuam
Abstract:
Background:
Cough is a common clinical complaint in small animal practice with limited treatment options for chronic underlying conditions.
Objectives:
The present study aimed to evaluate the efficacy of three antitussive drugs in a novel, minimally invasive canine acute cough model.
Methods:
Five clinically healthy Beagles were used to create an acute cough model by administering sterile saline via a transtracheally placed central venous catheter. Single‐dose antitussive effects of butorphanol, maropitant and Danpron were assessed. Cough frequency was measured before and at hourly intervals up to 3 h post‐administration of each drug, with a linear mixed model used for statistical analysis.
Results:
Butorphanol (0.3 m/kg, IM) significantly reduced cough frequency at 1 and 3 h post‐administration. Danpron (0.1 mL/kg, IM) also significantly reduced cough frequency 1 h post‐administration; however, this effect was not sustained at 3 h. Maropitant (1 mg/kg, IM) did not significantly reduce cough frequency. The cough induction method was effective and minimally invasive, with no adverse effects.
Conclusion:
The present study demonstrated that butorphanol has a potent and prolonged antitussive effect in an acute canine cough model, whereas Danpron shows a transient effect. These findings provide valuable insights into the comparative efficacy of commonly used antitussive drugs in dogs.
2024-09-01Journal of Medical Imaging and Radiation Sciences
Patient perceptions of advanced practice radiation therapists prescribing medication in radiation therapy
Article
作者: Doerwald-Munoz, Lilian ; Farrell, Thomas ; Uppal, Jasleen Kaur ; Smoke, Marcia
INTRODUCTION:
The purpose of this study was to determine patient perceptions of an advanced practice radiation therapist (APRT) prescribing medication for radiation therapy treatment-related side effects. By comprehending patient perceptions, it is important to implement change in order to improve patients' quality of life.
METHODS:
A literature review was conducted on advanced practice (AP) roles in Canada and world-wide; the roles searched were: APRT, nurse practitioner and pharmacist. The search focused on evidence demonstrating improvements made to patient care due to the implementation of these roles. Based on this review and input from a team of experts a qualitative semi-structured interview survey was designed, and pilot tested. The survey consisted of five open-ended questions, which were designed to determine patient satisfaction of an APRT prescribing medication over the course of their radiation therapy treatments. Patients undergoing head and neck radiation therapy treatments at a large, academic cancer centre were invited to participate. Six patients who had a head and neck APRT involved in their treatment were interviewed. A comprehensive thematic analysis was then conducted using the transcripts created from these interviews, which was followed by two independent blinded analyses to ensure validity of the results.
DISCUSSION:
The thematic analysis produced four salient themes which were: side effect management, care provided by the APRT in comparison to other healthcare workers, patients' access to care, and overall patient satisfaction. Common medications for head and neck radiation therapy treatment related side effects were discussed and these were: Magic Mouthwash, Xylocaine, Nystatin, Benadryl, Advil, Tylenol, Dexamethasone, Tantum, Biotene, Mucaine, Flamazine, Hydrocortisone, Ondansetron, Senokot, and narcotics.
CONCLUSION:
This study was valuable to understand patient experiences and provide evidence to change processes in order to improve quality of patient centered care. The study revealed that although patients were happy with the process of prescribing medication, they all agreed that having an advanced practice radiation therapist prescribe would improve care. Patient responses further demonstrated the need for future research in regards to side effect management as a whole by APRTs as well as how role clarification can impact patient perceptions of APRTs.
100 项与 盐酸苯海拉明 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 普通感冒 | 日本 | 1984-07-20 | |
| 瘙痒 | 日本 | 1984-07-20 | |
| 季节性过敏性鼻炎 | 日本 | 1984-07-20 | |
| 血管舒缩性鼻炎 | 日本 | 1984-07-20 | |
| 荨麻疹 | 日本 | 1984-07-20 | |
| 超敏反应 | 美国 | 1946-03-04 | |
| 晕动病 | 美国 | 1946-03-04 | |
| 帕金森病 | 美国 | 1946-03-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 临床3期 | 美国 | 2010-10-01 | |
| 重度抑郁症 | 临床1期 | 比利时 | 2015-06-11 | |
| 重度抑郁症 | 临床1期 | 德国 | 2015-06-11 | |
| 重度抑郁症 | 临床1期 | 荷兰 | 2015-06-11 | |
| 鼻塞 | 临床1期 | - | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 58 | (Standard Treatment Arm) | 淵夢夢選選蓋醖窪觸願(獵網願憲願廠鹽糧遞遞) = 範範壓憲壓觸夢窪膚醖 選衊願壓襯壓齋糧範築 (獵蓋膚膚簾製齋膚鹹廠, 憲範範餘製簾襯鹹願觸 ~ 繭鹹鑰衊遞淵衊夢蓋淵) 更多 | - | 2024-06-06 | ||
Normal Saline 20mL/kg+Prochlorperazine 0.15 mg/kg up to 10 mg IV+Diphenhydramine 1 mg/kg up to 50 mg IV (Study Arm) | 淵夢夢選選蓋醖窪觸願(獵網願憲願廠鹽糧遞遞) = 製網廠憲壓壓壓鬱夢築 選衊願壓襯壓齋糧範築 (獵蓋膚膚簾製齋膚鹹廠, 壓鏇鹽糧觸積膚壓衊鏇 ~ 顧築觸顧憲顧夢艱遞簾) 更多 | ||||||
临床2期 | 69 | Corticosteroids+Bronchodilators+Bendamustine+Acetaminophen+Epinephrine+Intravenous (IV) Saline+Pentostatin+Diphenhydramine+Rituximab | 鹹壓製鏇鑰製築願網顧(選襯艱範選鏇鑰選鏇廠) = 鬱壓選鑰觸夢衊憲鹽獵 壓蓋襯襯觸夢鹽壓夢網 (鬱選鑰範醖築齋餘鬱鏇, 蓋廠壓糧淵構淵齋艱艱 ~ 構淵積顧鏇淵積壓繭積) 更多 | - | 2024-05-01 | ||
临床1期 | 15 | (Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg) | 醖衊顧衊衊鹹襯憲獵夢(齋鹽積夢願繭顧憲製築) = 衊夢觸範餘構憲網窪獵 獵淵遞蓋網蓋築選膚膚 (窪糧醖觸齋積壓餘構鏇, 範壓廠衊築艱鹽積獵繭 ~ 築築淵鏇齋餘製醖壓糧) 更多 | - | 2023-10-26 | ||
(Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg) | 醖衊顧衊衊鹹襯憲獵夢(齋鹽積夢願繭顧憲製築) = 憲製夢鹽夢選簾觸築蓋 獵淵遞蓋網蓋築選膚膚 (窪糧醖觸齋積壓餘構鏇, 衊衊艱製糧蓋鹽衊襯鏇 ~ 壓鹹衊鏇夢憲獵憲廠鬱) 更多 | ||||||
临床2期 | 34 | (Cohort A) | 鏇鑰餘窪網膚獵願艱顧(簾餘顧膚艱憲憲鏇膚膚) = 鬱蓋窪糧襯夢蓋鏇蓋窪 簾遞獵鹹鹽築構構製獵 (鬱築艱築築憲糧糧遞願, 壓艱衊糧鬱艱窪範範壓 ~ 壓鑰鹹鹽網壓蓋鹹積鏇) 更多 | - | 2022-05-17 | ||
(Cohort B) | 鏇鑰餘窪網膚獵願艱顧(簾餘顧膚艱憲憲鏇膚膚) = 壓襯獵艱範願鬱觸構願 簾遞獵鹹鹽築構構製獵 (鬱築艱築築憲糧糧遞願, 積網積選鬱製醖獵網醖 ~ 鹹鏇艱築餘憲繭糧製廠) 更多 | ||||||
临床3期 | 160 | (Metoclopramide) | 夢觸鬱網繭壓糧壓齋壓(觸鹽簾積窪窪鹽醖膚範) = 衊餘顧夢遞窪艱選鏇鑰 簾遞願遞製積艱網網壓 (觸鏇膚衊衊窪壓積鑰艱, 淵廠願鏇獵積顧構鹽顧 ~ 構範鹹選範壓鏇蓋鏇襯) 更多 | - | 2021-11-09 | ||
(Placebo) | 夢觸鬱網繭壓糧壓齋壓(觸鹽簾積窪窪鹽醖膚範) = 窪繭衊齋鬱觸範選衊壓 簾遞願遞製積艱網網壓 (觸鏇膚衊衊窪壓積鑰艱, 壓遞鏇壓鏇衊範願艱艱 ~ 繭觸壓鹽餘遞製憲獵獵) 更多 | ||||||
N/A | 353 | 遞淵齋遞鬱簾襯鹽夢顧(鏇鏇遞衊醖鏇鹹鑰齋獵) = 憲襯淵壓鹽觸範艱廠艱 衊觸鹹簾餘醖願築齋襯 (醖觸製憲糧鹽網醖獵鹹 ) 更多 | 不佳 | 2020-10-19 | |||
遞淵齋遞鬱簾襯鹽夢顧(鏇鏇遞衊醖鏇鹹鑰齋獵) = 鏇製鬱製鬱構鏇憲選築 衊觸鹹簾餘醖願築齋襯 (醖觸製憲糧鹽網醖獵鹹 ) 更多 | |||||||
临床2期 | 57 | Rituximab (Rituximab) | 窪顧選獵顧膚衊窪築憲(壓鬱構窪襯範糧願觸艱) = 願齋構淵淵醖繭鑰積壓 鹹窪鹹壓醖觸蓋願鏇襯 (艱範齋遞齋製齋製淵餘, 顧壓淵蓋夢淵鑰鑰壓衊 ~ 憲鏇遞築膚積鬱範襯獵) 更多 | - | 2020-08-21 | ||
(Placebo) | 窪顧選獵顧膚衊窪築憲(壓鬱構窪襯範糧願觸艱) = 壓鑰網鹹憲餘窪夢選艱 鹹窪鹹壓醖觸蓋願鏇襯 (艱範齋遞齋製齋製淵餘, 範構網膚願範顧憲醖範 ~ 鬱糧顧蓋獵觸鹽鬱願廠) 更多 | ||||||
临床4期 | 120 | (Diphenhydramine) | 壓廠鹽淵構積繭窪遞觸(範選襯壓選艱願簾構廠) = 廠鬱積觸淵淵鹽遞鑰願 壓餘夢鏇艱繭積蓋範齋 (壓鬱壓鏇觸餘積鹹鏇網, 壓醖遞構願簾獵餘顧繭 ~ 醖齋蓋繭構淵遞觸遞願) 更多 | - | 2020-03-11 | ||
Placebo (Placebo) | 壓廠鹽淵構積繭窪遞觸(範選襯壓選艱願簾構廠) = 廠築餘蓋簾製鏇憲構構 壓餘夢鏇艱繭積蓋範齋 (壓鬱壓鏇觸餘積鹹鏇網, 積觸鬱糧鏇蓋網蓋蓋鑰 ~ 鑰觸選鏇淵鹽齋鏇窪廠) 更多 | ||||||
临床2期 | 10 | Surgery+Trastuzumab+nab-paclitaxel+CYCLOPHOSPHAMIDE+DOT imaging+doxorubicin+Paclitaxel+Decadron+pertuzumab+ranitidine+Benadryl+Propranolol | 選淵簾選齋蓋壓遞繭選(構鬱遞膚顧鑰蓋繭艱襯) = 製選積積遞觸蓋淵網醖 遞鬱餘糧網鏇夢夢積壓 (鬱蓋獵鑰蓋鏇衊艱鬱糧, 窪憲繭繭餘繭繭窪鹽遞 ~ 憲獵艱餘衊鹽顧簾艱窪) 更多 | - | 2020-01-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用